ω- carboxy aryl substituted diphenyl ureas as RAF kinase inhibitors
2000
(57) Abstract: The present invention includes the use of aryl ureas group in the treatment of raf-mediated disease, to pharmaceutical compositions for use in such therapies.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI